{
    "clinical_study": {
        "@rank": "1358", 
        "acronym": "pathfinder\u21225", 
        "arm_group": {
            "arm_group_label": "N8-GP", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted globally. The aim of the trial is to investigate safety, efficacy\n      and pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003\n      (N8-GP) in children with severe haemophilia A who have undergone treatment with previous\n      factor VIII (FVIII) products."
        }, 
        "brief_title": "A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients with severe congenital haemophilia A (FVIII activity level below 1%)\n\n          -  Weight above or equal to 10 kg\n\n          -  Documented history of 150 exposure days (ED) to FVIII products for patients aged 6-11\n             years and above 50 ED to FVIII products for patients aged 0-5 years\n\n        Exclusion Criteria:\n\n          -  Any history of FVIII inhibitors"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731600", 
            "org_study_id": "NN7088-3885", 
            "secondary_id": [
                "U1111-1129-6009", 
                "2012-001711-23", 
                "132214", 
                "P/0227/2012"
            ]
        }, 
        "intervention": {
            "arm_group_label": "N8-GP", 
            "description": "Fixed dose of N8-GP for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, N8-GP will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.", 
            "intervention_name": "NNC 0129-0000-1003", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 18, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016-7710"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70118-5720"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11040"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232-9830"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duisburg", 
                        "country": "Germany", 
                        "zip": "47051"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "GR-11527"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Hashomer", 
                        "country": "Israel", 
                        "zip": "52621"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vicenza", 
                        "country": "Italy", 
                        "zip": "36100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suginami-ku, Tokyo", 
                        "country": "Japan", 
                        "zip": "1670035"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania", 
                        "zip": "LT-08406"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "50400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal", 
                        "zip": "4200-319"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00935"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Luzern 16", 
                        "country": "Switzerland", 
                        "zip": "6000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmit", 
                        "country": "Turkey", 
                        "zip": "41380"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine", 
                        "zip": "83045"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 7EH"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "Germany", 
                "Greece", 
                "Israel", 
                "Italy", 
                "Japan", 
                "Lithuania", 
                "Malaysia", 
                "Portugal", 
                "Switzerland", 
                "Turkey", 
                "Ukraine", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Marianne Fridberg", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: National Health Surveillance Agency", 
                "Canada: Health Canada", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Paul-Ehrlich-Institut", 
                "Greece: National Organization for Medicines", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: The Italian Medicines Agency", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Lithuania: Ministry of Health", 
                "Malaysia: Ministry of Health", 
                "Portugal: INFARMED", 
                "Spain: Spanish agency of medicines and health care products", 
                "Switzerland: Federal Office of Public Health", 
                "Turkey: Ministry of Health Drug and Pharmaceutical Department", 
                "Ukraine: Ministry of Health Ukraine", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of inhibitory antibodies against coagulation factor VIII (FVIII) equal to or above 0.6 Bethesda units", 
            "safety_issue": "No", 
            "time_frame": "During the main phase of the trial (from 0-26 weeks of treatment)"
        }, 
        "removed_countries": {
            "country": "Brazil"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency of adverse events including serious adverse events reported during the trial period", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Haemostatic effect of N8-GP when used for treatment of bleeding episodes and assessed as: Excellent, Good, Moderate, or None", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Number of bleeding episodes during prophylactic treatment with N8-GP (annualised bleeding rate)", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Consumption of N8-GP per bleeding episode (number of injections)", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Consumption of N8-GP per bleeding episode (U/kg)", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Consumption of N8-GP during prophylaxis (number of injections)", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Consumption of N8-GP during prophylaxis ( U/kg per month and year)", 
                "safety_issue": "No", 
                "time_frame": "For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial)"
            }, 
            {
                "measure": "Incremental recovery (defined as the peak level recorded 60 min after end of injection) evaluated for FVIII product", 
                "safety_issue": "No", 
                "time_frame": "2-6 weeks prior to initial dosing with N8-GP and up to 30 hours after administration of previous FVIII product."
            }, 
            {
                "measure": "Incremental recovery (defined as the peak level recorded 60 min after end of injection) evaluated for N8-GP", 
                "safety_issue": "No", 
                "time_frame": "From 1 hour prior to and up to 96 hours after initial administration of N8-GP"
            }, 
            {
                "measure": "Area under the curve evaluated for FVIII product", 
                "safety_issue": "No", 
                "time_frame": "2-6 weeks prior to initial dosing with N8-GP and up to 30 hours after administration of previous FVIII product."
            }, 
            {
                "measure": "Area under the curve evaluated for N8-GP", 
                "safety_issue": "No", 
                "time_frame": "From 1 hour prior to and up to 96 hours after initial administration of N8-GP"
            }, 
            {
                "measure": "Terminal half-life evaluated for FVIII product", 
                "safety_issue": "No", 
                "time_frame": "2-6 weeks prior to initial dosing with N8-GP and up to 30 hours after administration of previous FVIII product."
            }, 
            {
                "measure": "Terminal half-life evaluated for N8-GP", 
                "safety_issue": "No", 
                "time_frame": "From 1 hour prior to and up to 96 hours after initial administration of N8-GP"
            }, 
            {
                "measure": "Clearance evaluated for FVIII product", 
                "safety_issue": "No", 
                "time_frame": "2-6 weeks prior to initial dosing with N8-GP and up to 30 hours after administration of previous FVIII product."
            }, 
            {
                "measure": "Clearance evaluated for N8-GP", 
                "safety_issue": "No", 
                "time_frame": "From 1 hour prior to and up to 96 hours after initial administration of N8-GP"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}